The startup’s filing comes during a broader biotech recovery that’s made some industry watchers optimistic IPOs could rebound ...

Hong Kong reclaims IPO leadership as tech and biotech listings surge Hong Kong tops global IPOs as AI, biotech and robotics ...

One of the biotech industry’s most esteemed venture capitalists anticipates that, after two years of drought, a wave of drug ...

Big Pharma-backed Aktis Oncology has announced plans to go public, in the latest encouraging sign for those betting on a ...

The biotech, which has a deal with Eli Lilly worth as much as $1.1 billion, is developing two targeted radiopharmaceuticals ...

MapLight Therapeutics is hoping to raise up to $262 million from its IPO, with the proceeds earmarked for its challenger to Bristol Myers Squibb’s schizophrenia med Cobenfy. The California-based ...

Aktis Oncology filed for an initial public offering in the United States on Friday, as stock market listings from the biotech ...

After pulling back from IPO attempts in 2022 and 2024, Cambridge-based Insilico Medicine has finally gone public with a ...

The U.S. IPO activity looks sluggish amid the holiday-shortened week. Nevertheless, the week prior saw Texas-based cybersecurity firm SailPoint price its upsized IPO of 60M shares at a public offering ...

Insilico Medicine, an artificial intelligence-driven drug discovery company backed by Qiming Venture Partners, made its debut ...

Drug developers aren’t expected to come back to the US equity markets in full force until next year — lagging other industries as biotechnology has delivered only subpar investor returns. Only five ...

Small and mid-cap biotech stocks entered 2025 like a compressed spring, and it finally snapped higher— here's why.